Multicenter Acute Stroke Trial-Europe "MAST-E"


Phase 3 Results

Trial Description

To assess the efficacy and safety of streptokinase in patients with acute ischemic stroke.


  • Streptokinase (Streptase┬«)Drug
    Intervention Desc: Thrombolytic agent

Trial Design

Double-blind, controlled trial of 310 patients at 48 centers in France and the UK.

Patient Involvement

156 patients were randomly assigned to receive streptokinase (1.5 million units over a period of one hour) and 154 received placebo. All were evaluated after 6 months.


Type Measure Time Frame Safety Issue
Primary A binary criterion combining mortality and severe disability at six months, with severe disability defined as a score of 3 or higher on the Rankin scale. The primary safety outcomes were mortality at 10 days and cerebral hemorrhage.
Secondary Death, recurrent cerebrovascular events, and ischemic events.